Valeant Pharmaceuticals has snapped up another dermatology specialist in its ongoing quest to build its business in the field. This time, it's PreCision Dermatology, a Cumberland, RI-based maker of prescription skin remedies and skin-care products sold by physicians.
Biotech management company NeXeption has locked in $21.5 million in a Series A round of financing to form Alexar Therapeutics, a company with a focus on treating skin disorders called inflammatory cutaneous disorders.
Spanish drugmaker Almirall is extending its global sales reach by picking up U.S.-based Aqua Pharmaceuticals for up to $400 million. The deal bolsters Almirall's presence in the red-hot dermatology field to boot.
Drugmakers have been wooing small players in the skin-treatment field, and just last month, Valeant Pharmaceuticals announced that it had agreed to buy Obagi Medical for $345 million. But now, Merz Pharma has trumped that bid.
Valeant Pharmaceuticals is socking another $350 million or so into the dermatology business. It's picking up the skin-care company Obagi Medical Products for $344 million in a $19.75-per-share buyout--just a few months after closing its $2.6 billion deal for Medicis Pharmaceutical.
Miami-based Brickell Biotech grabbed $7 million in a new venture round led by a South Korean cosmetics company to back its work on new chemical entities for dermatology.
Is 2013 the year that Sun Pharmaceutical Industries makes a European deal? Chairman Israel Makov tells Bloomberg that the Indian drugmaker is, in fact, scouting the region for deals.
Perrigo has further solidified its position in topical dermatology drugs, one of the areas in which prices have been escalating of late.
The end of the year M&A action seems to be on. Botox maker Allergan has agreed to pay $350 million to pick up skin products company, SkinMedica, Bloomberg reports.
India-based Sun Pharmaceutical is buying U.S. drugmaker DUSA Pharmaceuticals for about $230 million, or $8 per share, a 38% premium to yesterday's closing price.